NASDAQ · ABOS

Acumen Pharmaceuticals, Inc.

Closing price · Nov 13, 2026 $0.214

Latest quarter · ended Sep 30, 2026

Cash got weaker

descriptionFiled Oct 26, 2026

Cash from operationsBetter

−$26.7M

Dec '24Sep '26

vs. −$30.5M a year ago

Share countDiluting

+19.4%

Dec '24Sep '26

72.33M shares vs. 60.57M a year ago

Numbers come from the company's own 10-Q and 10-K reports filed with the SEC. Each bar is one quarter, oldest on the left. The colored bar is the latest. Hover over or tap a bar to see its number.

Smart money pulse

What insiders and funds are doing

Selling Insiders: as of Nov 13 Funds: as of Jun 30, 2026

account_balance
0 funds bought, 2 sold in the quarter ended Jun 30, 2026, counting funds that hold 500 stocks or fewer and $1M+ of this one. Index funds and banks are left out.
info
40 real insider sales in 12 months. $537K in total, not counting planned sales.

−100 means everyone selling, +100 everyone buying. This is data, not advice.

How the Pulse works

Pulse runs from −100 (everyone selling) to +100 (everyone buying). Half comes from insiders: real buyers vs. real sellers in the last 90 days (Form 4). Half comes from funds: funds that bought vs. funds that sold last quarter (13F). 13F is a snapshot of long positions on the last day of the quarter, filed up to 45 days later. It does not show short positions or trades since then.

Who owns it

98 funds report owning ABOS, up from 83

Holdings as of Jun 30, 2026

New33

Added21

Held30

Trimmed14

Sold out18

Last quarter

Who bought and who sold

Apr–Jun 2026

Adar1 Capital Management, LLC

−2%

Laurion Capital Management LP

Sold

Change in shares held from Mar 31 to Jun 30, 2026, biggest holdings first. Only funds that hold 500 stocks or fewer and $1M+ of this one: index funds and banks own almost everything, so their changes say little. Bars stop at ±100%.

Insider trades · last 12 months

Real buys and sales

● Open-market buy● Open-market sale

Last 6 months. A wider screen shows 12.

Showing 40 real trades. Hidden: 16 stock grants, 6 option exercises, 4 planned 10b5-1 sales. Those happen on a schedule and say little about what an insider thinks. Bigger dot means a bigger trade.

Real trades, newest first

Jun 17 Derrell Porter Director Open-market sale $30.4K 13,040 sh at $2.33 Sold 27% of stake

Jun 16 Derrell Porter Director Open-market sale $29.8K 12,800 sh at $2.33 Sold 27% of stake

Jun 15 Derrell Porter Director Open-market sale $15.2K 6,460 sh at $2.35 Sold 12% of stake

Jun 9 Nathan Fountain Director Open-market sale $14.3K 6,400 sh at $2.23 Sold 12% of stake

Jan 23 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $10.7K 5,633 sh at $1.90 Sold 3% of stake

Jan 22 Daniel OConnell CEO, Director Open-market sale $5.06K 2,689 sh at $1.88 Sold 1% of stake

Jan 22 Matt Zuga CFO & Chief Business Officer Open-market sale $3.14K 1,687 sh at $1.86 Sold 1% of stake

Jan 22 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $1.94K 1,054 sh at $1.84 Sold 1% of stake

Jan 22 Eric Siemers Chief Medical Officer Open-market sale $1.63K 895 sh at $1.82 Sold 1% of stake

Jan 22 Russell Barton COO Open-market sale $850 462 sh at $1.84 Sold 1% of stake

Show 30 older real trades

Jan 21 Daniel OConnell CEO, Director Open-market sale $16.9K 9,346 sh at $1.81 Sold 1% of stake

Jan 21 Matt Zuga CFO & Chief Business Officer Open-market sale $4.48K 2,473 sh at $1.81 Sold 1% of stake

Jan 21 Eric Siemers Chief Medical Officer Open-market sale $4.2K 2,331 sh at $1.80 Sold 1% of stake

Jan 21 Russell Barton COO Open-market sale $4.19K 2,315 sh at $1.81 Sold 1% of stake

Jan 21 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $4.07K 2,247 sh at $1.81 Sold 1% of stake

Jan 12 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $14.6K 8,548 sh at $1.71 Sold 9% of stake

Jan 12 Daniel OConnell CEO, Director Open-market sale $9.32K 5,388 sh at $1.73 Sold 1% of stake

Jan 9 Daniel OConnell CEO, Director Open-market sale $22.8K 12,941 sh at $1.76 Sold 2% of stake

Jan 9 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $9.15K 5,200 sh at $1.76 Sold 5% of stake

Jan 8 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $67.2K 36,911 sh at $1.82 Sold 27% of stake

Jan 8 Daniel OConnell CEO, Director Open-market sale $14.8K 8,143 sh at $1.82 Sold 1% of stake

Jan 8 Matt Zuga CFO & Chief Business Officer Open-market sale $12.5K 6,888 sh at $1.82 Sold 3% of stake

Jan 8 James Doherty President and CDO Open-market sale $11.8K 6,467 sh at $1.82 Sold 11% of stake

Jan 8 Russell Barton COO Open-market sale $6.57K 3,530 sh at $1.86 Sold 3% of stake

Jan 7 Daniel OConnell CEO, Director Open-market sale $75.1K 37,755 sh at $1.99 Sold 6% of stake

Jan 7 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $23.4K 11,770 sh at $1.99 Sold 8% of stake

Jan 7 Matt Zuga CFO & Chief Business Officer Open-market sale $11.6K 5,805 sh at $2.00 Sold 3% of stake

Jan 7 Russell Barton COO Open-market sale $3.38K 1,700 sh at $1.99 Sold 1% of stake

Jan 7 James Doherty President and CDO Open-market sale $3.38K 1,700 sh at $1.99 Sold 3% of stake

Jan 7 Amy Schacterle Chief Regulatory Officer Open-market sale $2.17K 1,097 sh at $1.98 Sold 12% of stake

Jan 6 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $21.5K 10,898 sh at $1.97 Sold 7% of stake

Jan 6 Eric Siemers Chief Medical Officer Open-market sale $13.5K 6,834 sh at $1.97 Sold 4% of stake

Jan 6 Daniel OConnell CEO, Director Open-market sale $10.1K 5,102 sh at $1.97 Sold 1% of stake

Jan 6 Matt Zuga CFO & Chief Business Officer Open-market sale $10K 5,100 sh at $1.97 Sold 2% of stake

Jan 6 Russell Barton COO Open-market sale $7.13K 3,618 sh at $1.97 Sold 3% of stake

Jan 5 Daniel OConnell CEO, Director Open-market sale $9.16K 4,649 sh at $1.97 Sold 1% of stake

Jan 5 Russell Barton COO Open-market sale $7.84K 4,000 sh at $1.96 Sold 3% of stake

Jan 5 Derek Meisner Chief Legal Officer & Corp Sec Open-market sale $7.84K 4,000 sh at $1.96 Sold 2% of stake

Jan 5 Eric Siemers Chief Medical Officer Open-market sale $7.84K 4,000 sh at $1.96 Sold 2% of stake

Jan 5 Matt Zuga CFO & Chief Business Officer Open-market sale $7.84K 4,000 sh at $1.96 Sold 2% of stake

Showing every filing. Dashed circles are routine: grants, tax withholding, option exercises and planned sales.

Top holders

Biggest funds in ABOS

As of Jun 30, 2026

Fund	Owns	Value	Change
Ra Capital Management, L.P.	29.0%	$56.1M	Same
Sands Capital Alternatives, LLC	5.1%	$9.93M	Same
BlackRock, Inc.	3.4%	$6.65M	+1296%
Alyeska Investment Group, L.P.	3.4%	$6.55M	Same
Franklin Resources Inc	3.2%	$6.15M	Same

"Owns" is shares reported divided by shares outstanding.